Reports
Sale
Canada Diabetes Market Size, Share, Trends, Analysis, Growth: By Type: Type 1, Type 2; By Drugs: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drugs, Combination Drugs; By Route of Administration: Oral, Subcutaneous, Intravenous; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Canada Diabetes Market Size
The Canada diabetes market was valued at USD 4.52 billion in 2023, driven by the increasing prevalence of the disease and the rising initiatives to improve diabetes management in the region. The market is expected to grow at a CAGR of 8.46% during the forecast period of 2024-2032, with the values likely to rise from USD 4.91 billion in 2024 to USD 9.40 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Canada Diabetes Market Outlook
- Recent data reveals that 1 in 3 Canadians are affected by diabetes or prediabetes. This indicates the high burden of the chronic condition which directly impacts market demand for effective diabetes treatment and management solutions.
- The Canada diabetes market share is influenced by the rising innovations in diabetes care technology and increased awareness campaigns on diabetes management.
- One of the major market trends is the growing investment in diabetes research to develop more effective treatments and prevent the complications associated with this chronic disease.
Canada Diabetes Market Analysis
Diabetes is a chronic disease characterized by the inability of the body to produce sufficient insulin or when the body cannot respond to the effects of insulin effectively, leading to high blood glucose levels. Type 2 diabetes is the most common type of diabetes where the body doesn’t make enough insulin or shows insulin resistance. Around 10% of people have Type 1 diabetes in which the immune system attacks and destroys insulin-producing cells. The rising innovations in diabetes care technology, such as closed-loop (artificial pancreas) systems for automated insulin delivery and continuous glucose monitoring (CGM) devices, are expected to drive the Canada diabetes market growth.
The increasing prevalence of diabetes which can be attributed to factors such as the growing aging population along with obesity rates, and lifestyle changes are significantly contributing to the global diabetes drugs market expansion. Recent data reveals that 1 in 3 Canadians are affected by diabetes or prediabetes. The prevalence rate of this chronic condition is estimated to increase by 26% in the next 10 years. This indicates the high burden of the disease which directly impacts the need for effective diabetes treatment and management solutions, thereby augmenting the Canada diabetes market demand.
The market share is also influenced by the increased initiatives aimed at spreading awareness about the risks of diabetes and the importance of early diagnosis. For instance, in November 2023, Diabetes Canada, a registered national charity that works to improve the quality of life of people living with diabetes, launched the Let’s Make Time campaign. With an aim to raise awareness about the disease in Canadians, this initiative educates people regarding the prevalence and complexity of diabetes, along with highlighting the time and effort needed to self-manage the chronic condition including calculating insulin doses, testing blood sugar, and filling syringes, among others. Such awareness campaigns on diabetes management are poised to elevate the market value.
One of the major Canada diabetes market trends is the rising investment in diabetes research to develop more effective treatments and prevent the complications associated with this chronic disease. In July 2023, the Government of Canada, in collaboration with the organization focused on type 1 diabetes research, Juvenile Diabetes Research Foundation (JDRF) Canada, announced an investment of USD 33 million to support 12 research projects focused on the prevention, detection, management, and treatment of diabetes. To advance screening for early-stage, pre-symptomatic type 1 diabetes, the funding will also support a national screening research consortium in Canada. Such intensive research initiatives, aided by substantial government funding, are projected to accelerate market growth in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Canada Diabetes Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Type | Type 1, Type 2 |
| Drugs | Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drugs, Combination Drugs |
| Route of Administration | Oral, Subcutaneous, Intravenous |
| Region | Northern Canada, British Columbia, Alberta, The Prairies, Central Canada, Atlantic Canada |
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Leading Players in the Canada Diabetes Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Medtronic
A global leader in medical technology, services, and solutions, Medtronic has a significant presence in the diabetes care sector. The company focuses heavily on innovation in diabetes technology such as the introduction of the MiniMed™ 780G system which is intended for continuous delivery of basal insulin at selectable rates.
Insulet Corporation
This company is known for its innovative Omnipod Insulin Management System, a tubeless insulin pump that offers an alternative to traditional tubed pumps.
LifeScan Inc.
California-based LifeScan is a key player in the field of blood glucose monitoring systems. They are widely known for their OneTouch brand of products that includes blood glucose meters, testing strips, and digital solutions for diabetes management.
Abbott Laboratories
This American multinational medical devices and healthcare company has a strong portfolio in diabetes care, including its popular FreeStyle Libre system that allows users to monitor their glucose levels without routine finger pricks.
Other players include Dexcom, Inc., Roche Diagnostic, Tandem Diabetes Care, and F. Hoffmann-La Roche Ltd, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Canada Diabetes Market Overview
3.1 Canada Diabetes Market Historical Value (2017-2023)
3.2 Canada Diabetes Market Forecast Value (2024-2032)
4 Canada Diabetes Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Canada Diabetes Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Canada Diabetes Type Success Rate
6 Canada Diabetes Epidemiology Scenario and Forecast
7 Canada Diabetes Market Landscape
7.1 Diabetes: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetes: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Drugs
8 Canada Diabetes Challenges and Unmet Needs
8.1 Canada Diabetes Type Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Canada Diabetes Type
10 Canada Diabetes Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Canada Diabetes Market Segmentation (2017-2032)
11.1 Canada Diabetes Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Type 1
11.1.3 Type 2
11.2 Canada Diabetes Market (2017-2032) by Drugs
11.2.1 Market Overview
11.2.2 Oral Anti-Diabetic Drugs
11.2.3 Insulin
11.2.4 Non-Insulin Injectable Drugs
11.2.5 Combination Drugs
11.3 Canada Diabetes Market (2017-2032) by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Subcutaneous
11.3.4 Intravenous
11.4 Canada Diabetes Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 Northern Canada
11.4.3 British Columbia
11.4.4 Alberta
11.4.5 The Prairies
11.4.6 Central Canada
11.4.7 Atlantic Canada
12 Northern Canada Diabetes (GvHD) Treatment Market (2017-2032)
12.1 Northern Canada Diabetes Market Historical Value (2017-2023)
12.2 Northern Canada Diabetes Market Forecast Value (2024-2032)
12.3 Northern Canada Diabetes Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Type 1
12.3.3 Type 2
12.4 Northern Canada Diabetes Market (2017-2032) by Drugs
12.4.1 Market Overview
12.4.2 Oral Anti-Diabetic Drugs
12.4.3 Insulin
12.4.4 Non-Insulin Injectable Drugs
12.4.5 Combination Drugs
13 British Columbia Diabetes (GvHD) Treatment Market (2017-2032)
13.1 British Columbia Diabetes Market Historical Value (2017-2023)
13.2 British Columbia Diabetes Market Forecast Value (2024-2032)
13.3 British Columbia Diabetes Market Overview
13.4 British Columbia Diabetes Market (2017-2032) by Type
13.4.1 Market Overview
13.4.2 Type 1
13.4.3 Type 2
13.5 British Columbia Diabetes Market (2017-2032) by Drugs
13.5.1 Market Overview
13.5.2 Oral Anti-Diabetic Drugs
13.5.3 Insulin
13.5.4 Non-Insulin Injectable Drugs
13.5.5 Combination Drugs
14 Alberta Diabetes (GvHD) Treatment Market
14.1 Alberta Diabetes Market Historical Value (2017-2023)
14.2 Alberta Diabetes Market Forecast Value (2024-2032)
14.3 Alberta Diabetes Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Type 1
14.3.3 Type 2
14.4 Alberta Diabetes Market (2017-2032) by Drugs
14.4.1 Market Overview
14.4.2 Oral Anti-Diabetic Drugs
14.4.3 Insulin
14.4.4 Non-Insulin Injectable Drugs
14.4.5 Combination Drugs
15 The Prairies Diabetes (GvHD) Treatment Market
15.1 The Prairies Diabetes Market (2017-2032) Historical Value (2017-2023)
15.2 The Prairies Diabetes Market (2017-2032) Forecast Value (2024-2032)
15.3 The Prairies Diabetes Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Type 1
15.3.3 Type 2
15.4 The Prairies Diabetes Market (2017-2032) by Drugs
15.4.1 Market Overview
15.4.2 Oral Anti-Diabetic Drugs
15.4.3 Insulin
15.4.4 Non-Insulin Injectable Drugs
15.4.5 Combination Drugs
16 Central Canada Diabetes (GvHD) Treatment Market
16.1 Central Canada Diabetes Market (2017-2032) Historical Value (2017-2023)
16.2 Central Canada Diabetes Market (2017-2032) Forecast Value (2024-2032)
16.3 Central Canada Diabetes Market (2017-2032) by Type
16.3.1 Market Overview
16.3.2 Type 1
16.3.3 Type 2
16.4 Central Canada Diabetes Market (2017-2032) by Drugs
16.4.1 Market Overview
16.4.2 Oral Anti-Diabetic Drugs
16.4.3 Insulin
16.4.4 Non-Insulin Injectable Drugs
16.4.5 Combination Drugs
17 Atlantic Canada Diabetes (GvHD) Treatment Market
17.1 Atlantic Canada Diabetes Market (2017-2032) Historical Value (2017-2023)
17.2 Atlantic Canada Diabetes Market (2017-2032) Forecast Value (2024-2032)
17.3 Atlantic Canada Diabetes Market (2017-2032) by Type
17.3.1 Market Overview
17.3.2 Type 1
17.3.3 Type 2
17.4 Atlantic Canada Diabetes Market (2017-2032) by Drugs
17.4.1 Market Overview
17.4.2 Oral Anti-Diabetic Drugs
17.4.3 Insulin
17.4.4 Non-Insulin Injectable Drugs
17.4.5 Combination Drugs
18 Regulatory Framework
19 Patent Analysis
19.1 Analysis by Drug Type of Patent
19.2 Analysis by Publication Year
19.3 Analysis by Issuing Authority
19.4 Analysis by Patent Age
19.5 Analysis by CPC Analysis
19.6 Analysis by Patent Valuation
19.7 Analysis by Key Players
20 Grants Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Application
20.5 Analysis by Funding Institute
20.6 Analysis by NIH Departments
20.7 Analysis by Recipient Organization
21 Clinical Trials Analysis
21.1 Analysis by Trial Registration Year
21.2 Analysis by Trial Status
21.3 Analysis by Trial Phase
21.4 Analysis by Therapeutic Area
21.5 Analysis by Geography
22 Funding and Investment Analysis
22.1 Analysis by Funding Instances
22.2 Analysis by Drug Type of Funding
22.3 Analysis by Funding Amount
22.4 Analysis by Leading Players
22.5 Analysis by Leading Investors
22.6 Analysis by Geography
23 Partnership and Collaborations Analysis
23.1 Analysis by Partnership Instances
23.2 Analysis by Drug Type of Partnership
23.3 Analysis by Leading Players
23.4 Analysis by Geography
24 Supplier Landscape
24.1 Market Share by Top 5 Companies
24.2 Medtronic
24.2.1 Financial Analysis
24.2.2 Product Portfolio
24.2.3 Demographic Reach and Achievements
24.2.4 Mergers and Acquisitions
24.2.5 Certifications
24.3 Insulet Corporation
24.3.1 Financial Analysis
24.3.2 Product Portfolio
24.3.3 Demographic Reach and Achievements
24.3.4 Mergers and Acquisitions
24.3.5 Certifications
24.4 LifeScan Inc.
24.4.1 Financial Analysis
24.4.2 Product Portfolio
24.4.3 Demographic Reach and Achievements
24.4.4 Mergers and Acquisitions
24.4.5 Certifications
24.5 Abbott Laboratories
24.5.1 Financial Analysis
24.5.2 Product Portfolio
24.5.3 Demographic Reach and Achievements
24.5.4 Mergers and Acquisitions
24.5.5 Certifications
24.6 Dexcom, Inc
24.6.1 Financial Analysis
24.6.2 Product Portfolio
24.6.3 Demographic Reach and Achievements
24.6.4 Mergers and Acquisitions
24.6.5 Certifications
24.7 Roche Diagnostic
24.7.1 Financial Analysis
24.7.2 Product Portfolio
24.7.3 Demographic Reach and Achievements
24.7.4 Mergers and Acquisitions
24.7.5 Certifications
24.8 Tandem Diabetes Care
24.8.1 Financial Analysis
24.8.2 Product Portfolio
24.8.3 Demographic Reach and Achievements
24.8.4 Mergers and Acquisitions
24.8.5 Certifications
24.9 F. Hoffmann-La Roche Ltd
24.9.1 Financial Analysis
24.9.2 Product Portfolio
24.9.3 Demographic Reach and Achievements
24.9.4 Mergers and Acquisitions
24.9.5 Certifications
25 Canada DiabetesCanada Diabetes Type - Distribution Model (Additional Insight)
25.1 Overview
25.2 Potential Distributors
25.3 Key Parameters for Distribution Partner Assessment
26 Key Opinion Leaders (KOL) Insights (Additional Insight)
27 Company Competitiveness Analysis (Additional Insight)
27.1 Very Small Companies
27.2 Small Companies
27.3 Mid-Sized Companies
27.4 Large Companies
27.5 Very Large Companies
28 Payment Methods (Additional Insight)
28.1 Government Funded
28.2 Private Insurance
28.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 4.52 billion in 2023 driven by the growing prevalence of diabetes in the region.
The market is anticipated to grow at a CAGR of 8.46% during the forecast period of 2024-2032, likely to reach a market value of USD 9.40 billion by 2032.
The advancements in diabetes care technology are fuelling the demand for the market.
One of the significant trends in the market is the rising investment in diabetes research. In July 2023, the Government of Canada, in collaboration with JDRF Canada, announced an investment of USD 33 million to support 12 research projects focused on the prevention, detection, management, and treatment of diabetes.
Based on the type, the market is segmented into type 1 and type 2 diabetes.
By route of administration, the market is divided into oral, subcutaneous, and intravenous.
Based on drugs, the market is divided into oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs.
The market segmentation by region includes Northern Canada, British Columbia, Alberta, the Prairies, Central Canada, and Atlantic Canada.
The key players in the market are Medtronic, Insulet Corporation, LifeScan Inc. (a subsidiary of Johnson & Johnson), Abbott Laboratories, Dexcom, Inc., and Roche.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER